Annuity-Based Pricing Models Could Mean Problems For Small Biotechs
Interest in annuity payment models is growing among companies and payers, but such models could be risk financial viability of small biotechs.
You may also be interested in...
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.
NICE will develop standards for using real world data as part of a new five-year strategic plan that the UK health technology assessment body hopes will make it a leader in the use of research and data.
International reference pricing is becoming more irrelevant as increasing emphasis is placed on other cost-containment measures.